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Meningococcal disease is one of the most dread-
ful conditions because of its propensity to aff  ect 
children and adolescents, its often fulminant 
course, and its tendency to cause epidemics (1, 
2). The incidence varies from 1 to 50 cases per 
100,000 but can reach much higher numbers 
during epidemics. Mortality ranges from 1 to 
10% in meningitis and from 20 to 40% in   sepsis, 
with up to 25% of the survivors develop ing per-
manent neurological sequelae (2). The  causative 
agent, Neisseria meningitidis, is an encapsulated 
bacterium classifi   ed into diff  erent  serogroups 
based on the chemical composition and immu-
nologic features of the capsular polysaccharide 
(CP) (3). Human isolates are almost totally ac-
counted for by fi  ve serogroups (A, B, C, Y, 
and W135), with A, B, and C accounting for 
>90% of all infections. Group A strains cause 
large epidemics in developing countries, whereas 
group B, C, or Y strains are prevalent in   Europe 
and the United States (4). The main virulence 
factor of these organisms is the CP, which pro-
tects against complement-mediated bacterioly-
sis and phagocytosis. Polysaccharide vaccines 
against serogroups A, C, Y, and W135 have 
been available for decades but are not eff  ective 
in the age groups that are most susceptible to 
the disease (i.e., infants and young children). Re-
cently developed polysaccharide–protein con-
jugate vaccines, however, are likely to overcome 
this limitation (5, 6). No vaccine is currently 
available for the prevention of infections caused 
by serotype B strains, which often account for 
more that half of meningococcal disease cases 
in developed countries (4). Major obstacles to 
the development of capsule-based vaccines are 
the poor immunogenicity of the group B poly-
saccharide (even after protein conjugation) and 
concerns over the induction of autoantibodies 
(7). These features are probably related to the 
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against MenB and other encapsulated bacteria.
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structural identity between serogroup B N. meningitidis 
(MenB) CP and human polysialic acid (PSA), both consisting 
of  α(2→8)N-acetyl neuraminic acid. To circumvent this 
problem, the immunogenicity of various derivatives of the 
MenB CP was tested (8). A protein-conjugated polysaccha-
ride in which the N-acetyl groups of the sialic acid residues 
were replaced with N-propionyl groups induced bactericidal 
IgGs, which protected mice against experimental infection 
(8, 9). Further studies using mAbs defi  ned two diff  erent 
classes of capsular epitopes naturally present on the meningo-
coccal surface (10–12). One class is cross-reactive with   human 
PSA, whereas the other is non–cross-reactive and protective. 
Therefore, a reasonable approach may involve immunization 
with mimics of the protective epitope. Using the bactericidal 
non–cross-reactive mAb Seam 3 as a template (11), we devel-
oped antiidiotypic antibody single chain variable fragments 
(scFvs), which could induce, after immunization, human 
non–cross-reactive anticapsular IgGs (13). These antibodies, 
however, could not consistently produce serum bactericidal 
activity, likely because of their insuffi   cient  avidity  and/or 
concentration. Although bactericidal activity is only one as-
pect of host defense and may underestimate the effi   cacy of 
vaccines directed against MenB (14, 15), it remains the hall-
mark of protection in humans and is desirable in vaccine 
  development. In this paper, we sought to increase the immu-
nogenicity of our scFv constructs by exploiting their adapt-
ability for DNA vaccination. This is a logical extension of the 
use of recombinant mimics and off  ers many practical advan-
tages, including ease of manipulation and production of the 
immunogen (16–18). After exploring diff  erent strategies, we 
were able to induce satisfactory bactericidal activity and pro-
tection against experimental MenB infection by immuniza-
tion with scFv gene–containing plasmids devoid of a secretory 
signal sequence. These data may be useful in the develop-
ment of eff  ective immunogens for the prevention of diseases 
caused by encapsulated bacteria.
RESULTS
In vitro scFv expression
In initial experiments, COS-7 cells were transiently trans-
fected with a plasmid containing the G1 scFv gene fused to 
an adenoviral secretory signal peptide sequence (pS.scFvG1; 
Table I). Protein expression was analyzed by the ability of 
permeabilized cells to bind the Seam 3 mAb (e.g., the antigen 
against which the G1 scFv was raised) using immunofl  uores-
cence fl  ow cytometry. After treatment with Seam 3 followed 
by FITC-conjugated anti–mouse IgG, pS.scFvG1-transfected 
cells showed increased fl   uorescence relative to cells trans-
fected with the empty plasmid (Fig. 1). Increased fl  uores-
cence was not detected when cells were treated with an 
irrelevant, isotype-matched mAb in place of Seam 3 (not 
  depicted). These data indicated that pS.scFvG1 transfection 
resulted in the expression of the G1 scFv in a functional form, 
as defi  ned by its ability to bind to the Seam 3 idiotope.
Figure 1.  Flow cytometry analysis of in vitro expression of the 
scFv. Binding of Seam 3 mAb to permeabilized COS-7 cells transfected 
with an expression plasmid containing the scFv G1 gene (bottom, 
pS.scFvG1) or the empty vector pCI-neo (top). After being transiently 
transfected, cells were permeabilized and exposed to the Seam 3 mAb. 
FITC-conjugated anti–mouse IgG was used to detect Seam 3 binding. 
Horizontal lines indicate the gates that were defi  ned to exclude back-
ground binding.
Table I. Plasmids used
Description   Leader sequencea   T helper sequenceb Antigenic sequence
pCI-neo  –   –   –
pS.scFvG1 M  R  Y  M  I  L  G  L  L  A  L  A  A  V  C  S  A  A  E  F   –   G1  scFvc
pT.scFvG1  – M  K  L  Q  Y  I  K  A  N  S  K  F  I  G  I  T  E  L  E  F   G1  scFv 
pST.scFvG1  M  R  Y  M  I  L  G  L  L  A  L  A  A  V  C  S  A  A   Q  Y  I  K  A  N  S  K  F  I  G  I  T  E  L  E  F   G1  scFv 
pscFvG1  –   –   G1  scFv 
aUnderlined is the leader sequence from a 19-kD glycosylated membrane protein of human adenovirus C, serotype 2 (available from the National Center for Biotechnology 
Information [NCBI] under accession no. CAC67720, aa 1–18), which was previously used in the design of vaccination plasmids (reference 30).
bUnderlined is the T helper sequence from tetanus toxin (available from NCBI under accession no. AAK72964, aa 831–845), which was previously used in the design of 
vaccination plasmids (reference 19).
cAvailable from NCBI under accession no. AAQ83756, aa 1–248.JEM VOL. 203, January 23, 2006  113
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Vaccination with the scFv gene induces serum 
bactericidal activity
Next, mice were injected i.m. with diff  erent doses of pS.
scFvG1 or empty plasmid, and serum bactericidal antibodies 
were measured at various times after immunization. Results 
were compared with those observed after immunization with 
the G1 scFv protein conjugated with KLH using Freund’s 
adjuvant. Bactericidal titers were always <9 (i.e., below the 
detection limit of the assay) in serum samples obtained before 
or after immunization with the empty plasmid (Fig. 2 A). 
Only two out of eight animals developed a bactericidal re-
sponse (with titers of 36 and 72) after immunization with G1 
scFv–KLH, which was in agreement with previous experi-
ments (13). The eff  ects of pS.scFvG1 immunization on se-
rum bactericidal activity were markedly dose dependent (Fig. 
2 A). Using 150 μg, fi  ve out of eight animals produced bac-
tericidal responses with titers ranging from 36 to 144. These 
data indicated that immunization with the scFv gene but not 
with the corresponding protein frequently resulted in serum 
bactericidal activity even though only moderately elevated 
titers were observed.
One of the advantages of DNA immunization is the pos-
sibility to easily manipulate the immunogen to link it, for ex-
ample, to additional epitopes or immunostimulatory peptides. 
Therefore, in further experiments, we fused the G1 scFv 
gene with a universal T helper cell sequence to generate plas-
mid pST.scFvG1 (19). Constructs containing the scFv gene 
without the adenoviral leader peptide sequence were also 
tested (pT.scFvG1 and pscFvG1; Table I). After three immu-
nizations with these plasmids, bactericidal titers were assessed 
in sera obtained at 56 d after the fi  rst administration. For 
comparison, we also tested sera from animals immunized 
with N-propionylated MenB CP (N-Pr MenB) conjugated 
with tetanus toxoid (TT). We used this conjugate because 
it contains the epitope mimicked by the G1 scFv and can 
elicit high levels of anti–MenB CP antibodies when used in 
Freund’s adjuvant (8, 13). Vaccination with plasmids devoid 
of a signal peptide sequence resulted in bactericidal titers that 
were markedly higher than those induced by the correspond-
ing plasmids bearing such a sequence and that were similar to 
those of animals vaccinated with the N-Pr MenB–TT in 
Freund’s adjuvant (Fig. 2 B). The presence of a T cell epitope 
sequence in the immunizing plasmid was associated with a 
slight increase in antibody titers, although this eff  ect did not 
reach statistical signifi  cance. These data indicated that immu-
nization with the G1 scFv gene devoid of a secretory signal 
sequence was eff  ective in inducing high-level serum bacteri-
cidal activity.
Specifi  city of the antibodies induced by DNA vaccination
Next, we verifi  ed that the antibodies induced by scFv gene 
immunization were directed against their intended target, 
that is the MenB CP. In these experiments, we focused on 
sera obtained from pT.scFvG1-immunized animals because 
these sera showed the highest titers (Fig. 2 B). The bacteri-
cidal activity of such sera was inhibited, in a dose-dependent 
fashion, by purifi  ed N-Pr MenB CP or the G1 scFv protein 
but not by a control, irrelevant scFv (designated H6; Fig. 3 A). 
Moreover, bactericidal activity was observed only with encap-
sulated MenB strains, but not with serogroups MenA or MenC 
(Fig. 3 B). These data indicated that vaccination with the G1 
scFv gene induced anti-scFv antibodies that specifi  cally cross 
reacted against the MenB capsule, thereby producing bacte-
rial killing. Although we have previously shown that the 
Figure 2.  Bactericidal activity in sera from scFv-immunized mice. 
(A) Serum bactericidal activity in mice immunized with different doses 
(25, 75, and 150 μg) of an expression plasmid containing the scFv G1 
gene fused to a signal peptide sequence (pS.scFvG1) or with 150 μg of 
the G1 protein (G1 scFv–KLH). Sera from mice administered with the 
empty vector (pCI-neo) were used as controls. Arrows indicate immuniza-
tion times. Data represent geometric means + SD of eight determina-
tions, with each conducted in duplicate on a different animal. *, P < 0.05 
compared with empty vector sera as determined by ANOVA and 
Student-Newman-Keuls test. (B) Bactericidal titers in sera from mice 
  immunized with various types of G1 scFv gene–containing plasmids 
(for a description see Table I). 10 animals per group were immunized 
on days 0, 21, and 42 with 150 μg DNA in PBS i.m. or, for comparison, 
with N-Pr MenB–TT (4 μg sialic acid) s.c. in CFA (day 0) and IFA (days 21 
and 42). Sera were collected at day 56. Each marker indicates data from 
an individual mouse with mean geometric titers represented by a 
  horizontal bar. P < 0.05, as determined by ANOVA and Student-
Newman-Keuls test.114  ANTI-MENB DNA VACCINATION | Beninati et al.
  antibodies induced by our antiidiotypic protein did not cross 
react with human PSA (13), it was of interest to verify that 
this also occurred after DNA immunization, especially in 
consideration that the latter can broaden the repertoire of 
recognized epitopes (20). Therefore, sera from pT.scFvG1-
immunized animals were tested against neuraminidase-treated 
or untreated cells from the CHP 212 human cell line express-
ing high levels of PSA. The Seam 26 mAb, which is known 
to react with both human and MenB PSA, was used as a pos-
itive control. As expected, this mAb showed strong reactivity 
against untreated, but not neuraminidase-treated, cells (Fig. 
3 C). Immune sera were totally devoid of reactivity against 
either untreated or neuraminidase-treated CHP 212 cells, in-
dicating that human PSA cross-reactive antibodies were not 
induced by scFv gene immunization.
Because the antibodies cross reacting with the MenB sur-
face should be a fraction of anti–G1 scFv antibodies, in   further 
experiments we determined whether there was a correlation 
between serum bactericidal activity and total anti-scFv titers. 
To this end, serum samples from animals immunized with 
  either the scFv-KLH protein (from the experiments reported 
in Fig. 2 A) or the pT.scFvG1 plasmid (from the experiments 
reported in Fig. 2 B) were tested for antibody binding to 
plates sensitized with the G1 scFv. These groups of sera were 
chosen because they diff  ered widely in bactericidal activity. 
Surprisingly, however, they did not diff  er in reactivity against 
the scFv (Fig. 4, A and B), suggesting that DNA immuniza-
tion selectively increased the fraction of anti–G1 scFv 
  antibodies that cross reacted with MenB and caused bacteri-
cidal activity.
To determine the isotype distribution of anti-MenB anti-
bodies, we used an ELISA assay in which plates were sen-
sitized with whole meningococcal cells. Preimmune sera 
showed some background reactivity that was mostly ac-
counted for by IgM (Fig. 4 C). Antibody binding was signifi  -
cantly higher in immune sera, with a predominance of IgG2a 
(Fig. 4 D). These data suggested that immunization with the 
G1-containing plasmid induced a Th1-type response and that 
IgG2a, which can mediate complement-dependent bacterial 
killing (11), likely accounted for the observed serum bacteri-
cidal responses.
Protective effects of passively administered antibodies
To completely assess the functional properties of the antibody 
response induced by scFv gene immunization, we ascer-
tained the ability of immune sera to passively protect infant 
rats against meningococcal bacteremia. In these experiments 
we measured the number of blood CFU in pups inoculated 
with pools of sera obtained before or after pT.scfvG1 immu-
nization and challenged i.p. with MenB strain 2996. As 
  positive controls, groups of pups were treated with a pool of 
sera from N-Pr MenB–TT–immunized animals or with the 
Seam 3 mAb. Pretreatment with the pT.scfvG1 immune 
serum pool (diluted up to 1:8) (P < 0.05) signifi  cantly pro-
tected pups from bacteremia (Table II). These eff  ects were 
similar to those observed with the serum pool from N-Pr 
MenB–TT–immunized animals. In contrast, animals inocu-
lated with a preimmune serum pool or with a pool obtained 
after immunization with the empty plasmid were not pro-
tected (Table II). These data indicated that immunization 
Figure 3.  Immunization with the scFv gene induces capsule-spe-
cifi  c antibodies. (A) Inhibition of bactericidal activity by increasing doses 
of purifi  ed N-Pr MenB CP (MenB CP) or the G1 scFv protein. An irrelevant 
scFv (designated H6) was used as a control. A serum sample (with a bac-
tericidal titer of 576) from an animal immunized with the pT.scFvG1 plas-
mid was mixed with the inhibitors and tested in the bactericidal assay at a 
fi  nal dilution of 1:300. Data represent CFU counted after completion of 
the assay. This experiment is representative of three, with each conducted 
on a different serum sample. (B) Bactericidal activity against different 
meningococcal strains of serum samples obtained from pT.scFvG1-immu-
nized animals. The indicated MenB, MenA, and MenC strains were tested. 
Data represent geometric means and SD from fi  ve determinations, with 
each conducted on a different animal. (C) Reactivity against human PSA 
of sera from pT.scFvG1-immunized animals. Neuraminidase-treated or 
untreated cells from the PSA-rich CHP 212 human neuroblastoma cell line 
were fi  xed in the wells of microtiter plates. Sera were diluted 1:20 and 
tested for binding to cell-coated plates by ELISA. Seam 3 and Seam 26 
mAbs were used, respectively, as negative and positive controls at a con-
centration of 5 μg/ml. Data represent means + SD of fi  ve determinations 
conducted with the same serum samples used in B. Preimmune and im-
mune samples were collected, respectively, on days 0 and 56 after the 
fi  rst immunization.JEM VOL. 203, January 23, 2006  115
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with pT.scFvG1 induced serum antibodies capable of aff  ord-
ing passive protection against systemic spreading of MenB.
DISCUSSION
Capsule-based vaccines are not available for the prevention 
of MenB infection because the MenB CP is cross-reactive 
with human tissue and is not immunogenic, even after pro-
tein conjugation. This is a serious problem, because MenB 
strains can account for up to 80% of devastating meningo-
coccal disease in developed countries (2, 11). Because distinct 
human cross-reactive and non–cross-reactive epitopes exist 
on the MenB surface (11, 12), it was possible to induce anti-
capsular antibodies and at the same time avoid the risk of au-
toimmunity by mimicking a single non–cross-reactive epitope 
of the MenB CP (13). However, the antibodies induced by 
our surrogate antigen were of insuffi   cient avidity and/or con-
centration to consistently induce bacterial killing, which is an 
accepted marker of vaccine-induced protection in humans. 
This is not surprising, because the induction of weak anti-
body responses has been a problem with many antigenic 
mimics, including peptide mimotopes or antiidiotypic anti-
bodies (21).
After exploring diff  erent strategies in this paper, it was 
possible to consistently induce bactericidal and protective ac-
tivity in the sera of animals immunized with the gene encod-
ing for our scFv mimic. Serum bactericidal activity was totally 
accounted for by scFv-specifi  c antibodies that cross reacted 
with the MenB capsule, as shown by complete abrogation of 
killing by competing G1 scFv or MenB CP. Moreover, im-
mune sera could not kill meningococci with MenA or MenC 
capsules. The antibodies induced by scFv gene immunization 
were predominantly of the IgG2a isotype, which is typical of 
a Th1 response. Finally, the induced antibodies were non–
cross-reactive with human PSA.
The importance, in terms of protection in humans, of 
the bactericidal responses observed in our experiments after 
scFv gene vaccination remains, of course, to be established. It 
should be noted, in this respect, that bactericidal activity was 
tested using rabbit complement, which produces consider-
ably higher bactericidal titers than human complement (22). 
Nevertheless, it is encouraging that the antibodies induced by 
scFv gene immunization were protective in a well character-
ized in vivo model, such as the infant rat model.
This paper illustrates the potential of DNA vaccination–
based strategies to augment antibody responses against pro-
tein mimetics. The versatility and ease of manipulation of 
Figure 4.  Measurement of anti-scFv and anti-MenB antibodies in 
sera from scFv gene–immunized mice. Serum samples obtained from 
mice immunized with the scFv protein (A) or the pT.scFvG1 plasmid 
(B) were tested at a 1:300 dilution for antibody binding to plates sensi-
tized with the G1 scFv. Binding was measured by ELISA using IgM- and 
IgG-specifi  c reagents. For each group, fi  ve serum samples, each obtained 
from a different animal, were tested. (C and D) Isotype distribution of 
anti-MenB antibodies in sera from animals immunized with the G1 scFv 
gene. Sera from pT.scFvG1-immunized animals were tested at a 1:200 
(C) or a 1:100 (D) dilution for antibody binding to bacteria-coated plates. 
Antibody binding was detected by ELISA using isotype-specifi  c reagents. 
Data represent means and SD from fi  ve determinations, with each con-
ducted on a different animal. Preimmune and immune samples were col-
lected, respectively, on days 0 and 56 after the fi  rst immunization.
Table II. Passive protection from bacteremia of infant rats 
challenged with MenB
Sample
CFU/ml
(geometric mean)a
Number of
protected 
rats/totalb
Seam 3 mAb–positive control (2 μg) <100  8/8
PBS 384,514  0/8
preimmune serum pool diluted 1:2 161,542   0/8
pCI-neo (empty vector)
  immune serum pool diluted 1:2
122,893  0/8
N-Pr MenB–TT
  immune serum pool diluted 1:2
<100  8/8*
N-Pr MenB–TT
  immune serum pool diluted 1:4
<100  8/8*
N-Pr MenB–TT
  immune serum pool diluted 1:8
136  7/8*
N-Pr MenB–TT
  immune serum pool diluted 1:16
207  5/8*
pT.scFvG1
  immune serum pool diluted 1:2
<100  8/8*
pT.scFvG1
  immune serum pool diluted 1:4
<100  8/8*
pT.scFvG1
  immune serum pool diluted 1:8
102  6/8*
pT.scFvG1
  immune serum pool diluted 1:16
666  4/8
Infant rats were treated i.p. with 100 µl of serum dilutions or with the control Seam 
3 mAb. 2 h after treatment, the pups were challenged i.p. with 8 × 103 CFU MenB 
strain 2996. Blood cultures were obtained at 18 h after challenge. *, signifi  cantly 
different from preimmune serum pool using Fisher’s exact test.
aFor determination of geometric means, culture-negative animals were assigned an 
arbitrary value of 50 CFU/ml (i.e., half of 100 CFU/ml, the lower limit of detection).
bPups were considered protected from bacteremia in the presence of a negative 
blood culture.116  ANTI-MENB DNA VACCINATION | Beninati et al.
gene vaccination allowed us to quickly and effi   ciently screen 
several approaches, including the addition of T helper epi-
topes (23, 24). Unexpectedly, the most successful strategy 
that resulted in markedly augmented bactericidal titers in-
volved deletion of the secretory signal peptide sequence ini-
tially placed before the scFv (Fig. 2 B). In DNA vaccination, 
homologous or heterologous signal sequences are generally 
used to direct the antigen into the endoplasmic reticulum of 
the transfected cell, thus leading to secretion, with the ratio-
nale of augmenting availability of the immunogen for uptake 
by antigen-presenting cells. However, there are few data on 
the relationships between the cellular localization of the anti-
gen and the type and extent of the immune response. In a 
comparative study, two plasmids either containing or lacking 
a signal sequence produced similar antibody levels despite 
diff  erential intracellular targeting of the encoded antigen 
(25). In another study, cytoplasmic ovalbumin induced lower 
IgG1 but higher IgG2a than secreted ovalbumin (26). Inter-
estingly, mouse immunization with a plasmid encoding a 
modifi  ed version of carcinoembryonic antigen (CEA), de-
void of its signal peptide and fused to a T helper epitope, re-
sulted in higher anti-CEA antibody levels relative to those 
observed using the wild-type CEA plasmid (27). Further 
studies will be necessary to clarify whether the mechanisms 
underlying the eff  ects reported in these papers, as well as in 
the present one, involve diff  erential antigen uptake and/or 
processing by antigen-presenting cells. Irrespective of the 
mechanisms involved, our data strongly indicate that manip-
ulation of secretory signals deserves further exploration in the 
challenging task of optimizing antiinfectious DNA vaccines. 
In our hands, removal of secretory signals recently proved 
highly eff  ective in increasing the immunogenicity of two ad-
ditional unrelated mimics (unpublished data). Thus, this 
strategy may be widely applicable in the fi  eld of peptide mi-
motopes or recombinant antiidiotypes.
Interestingly, in this study immunization with the G1 
scFv gene induced total anti–G1 scFv antibody levels that 
were similar, by ELISA, to those induced by the correspond-
ing protein (Fig. 4, A and B). Yet, as discussed above, bacte-
ricidal activity was markedly higher after gene vaccination. 
This suggests that (a) a heterogeneous response is induced by 
scFv immunization, in which only a portion of the induced 
antibodies is cross-reactive with the MenB CP, and (b) MenB 
cross-reactive antibodies are preferentially induced by gene, 
not protein, scFv immunization. One of the interesting fea-
tures of genetic immunization, which may perhaps explain 
these fi  ndings, is its ability to change the hierarchy of immu-
nodominance of the recognized epitopes relative to that in-
duced by conventional immunization. For example, DNA 
encoding for the mycobacterial antigen Ag85 increased the 
number of recognized Ag85 T cell epitopes over those rec-
ognized after immunization with live bacteria and changed 
the hierarchy of immunodominance in favor of the newly 
recognized epitopes (20).
Studies are underway to determine the epitope specifi  city 
and relative frequency of B cell and T cell subpopulations ac-
tivated by scFv gene, compared with protein, immunization. 
We are also testing the hypothesis that the increased func-
tional activity of the antibodies induced by gene vaccination 
is related to the adjuvant-like properties of the immunizing 
plasmids (23). Interestingly, major adjuvant-dependent dif-
ferences have been documented in the ability of N-Pr MenB, 
the antigen mimicked by our scFv, to induce bactericidal 
  activity. For example, N-Pr MenB–TT induced bactericidal 
activity when given in Freund’s adjuvant (8, 13) but not in 
alum (28). In contrast, a conjugate of N-Pr MenB with porin 
B, a protein with adjuvant-like properties (29), could induce 
bactericidal activity using either adjuvant (28).
Our data are in general agreement with previous reports 
dealing with immunization with minigenes encoding for 
  pep  tide mimotopes. DNA vaccination was recently used to 
redirect the immune system from a Th2 to a more eff  ective 
Th1 response (30). Moreover, a similar approach was suc-
cessful in inducing serum bactericidal activity against MenC 
CP (31) and antibodies directed against the type 4 pneumo-
coccal CP (32).
Collectively, these data indicate that DNA immunization 
off  ers new ways of stimulating the immune system and suggest 
that these features can be exploited in the prevention of diseases 
caused by encapsulated bacteria. This is especially relevant for 
infections, such as those caused by MenB, for which no   vaccine 
is available because of the failure of conventional approaches. 
Moreover, despite considerable success, existing conjugate vac-
cines are not without problems, including complexities in poly-
saccharide production and conjugation. These diffi   culties can 
become particularly challenging with vaccines consisting of 
multiple conjugates. In contrast, it seems relatively easy to clone 
diff  erent mimics in a single vector for vaccinating against path-
ogens with multiple serotypes. Thus, the global use of vaccines 
directed against encapsulated bacteria would be facilitated by 
the development of eff  ective DNA vaccines, especially in con-
sideration of some additional advantages such as their low cost 
and independence from the cold chain.
MATERIALS AND METHODS
Bacterial strains and reagents. Meningococcal strains 2996, 8047, and 
MC58 (MenB), F8238 and A1 (MenA), and C11 (MenC) were provided by 
M.M. Giuliani (Chiron Corp., Siena, Italy). Purifi  ed N-Pr MenB CP and 
the Seam 3 and Seam 26 mAbs were provided, respectively, by A. Bartoloni 
and M. Mariani (Chiron Corp., Siena, Italy). The G1 and the irrelevant H6 
scFvs were expressed recombinantly in Escherichia coli and purifi  ed as previ-
ously described (13, 18, 33). For immunization experiments, the G1 scFv–
KLH and the N-Pr MenB–TT conjugates were prepared as previously 
described (13).
DNA constructs and expression analysis. To generate plasmids for DNA 
vaccination (Table I), we used pCI-neo, a mammalian expression vector 
(Promega). The G1 scFv–encoding sequence was PCR-amplifi  ed as pre-
viously described (13–18) and ligated into the multiple cloning site of pCI-
neo, generating pscFvG1. In the design of pS.scFvG1, the leader sequence 
was inserted at the beginning (i.e., at the 5′ NheI/EcoRI fl  anking site) of the 
G1 scFv gene. To produce the pT.scFvG1, a tetanus toxin universal T helper 
cell epitope (19) was inserted at the beginning of the scFv. Finally, a plasmid 
(pST.scFvG1) was generated containing both the secretory sequence and the 
T helper cell epitope before the scFv gene.JEM VOL. 203, January 23, 2006  117
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Plasmid preparation. Plasmids for in vitro transfection or mouse immu-
nization were grown in E. coli DH5α and purifi  ed using EndoFree Plasmid 
Maxi or Giga kits (QIAGEN). Each lot of plasmid DNA had a A260/A280 
  ratio ≥1.8 (as determined by UV spectrophotometry), endotoxin content 
≤0.1 EU/μg DNA (as determined by Limulus Amebocyte Lysate assay kit; 
Associates of Cape Cod Inc.), and a predominantly supercoiled form.
FACS analysis. The ability of engineered DNA constructs to express func-
tional G1 scFv was analyzed by fl  ow cytometry. A subconfl  uent monolayer 
of COS-7 cells (CCL-70, a monkey kidney fi  broblast cell line; American 
Type Culture Collection) was transiently transfected with 2.5 μg of vector 
DNA per 106 cells in a synthetic cationic lipid solution (TransFast; Pro-
mega). The pCI-neo mammalian vector (empty vector) was used as a 
  control. After 48 h, the transfected cells were washed in PBS (0.01 M phos-
phate, 0.15 M NaCl, pH 7.2), trypsin treated, and fi  xed overnight with 
1 ml paraformaldehyde (2.5 mg/ml). The cells were then permeabilized 
with 1 ml PBS containing 0.2% (vol/vol) Tween 20 (PBS-Tween) and in-
cubated with the Seam 3 mAb (4 μg/ml in PBS) for 2 h at 37°C. 10 μg/ml 
FITC-labeled rabbit anti–mouse IgG (Abcam Ltd.) was used to detect 
bound Seam 3.
Immunizations. For DNA immunization, 6–8-wk-old BALB/c mice 
(Charles River Laboratories) were injected in the quadriceps muscle with 
purifi  ed DNA at the doses indicated in the fi  gures in 50 μl of PBS. Mice 
were immunized on days 0, 21, and 42 with equal plasmid doses, and tail 
veins were bled on days 0, 36, and 56 to obtain sera. Moreover, groups of 
mice were immunized with scFv G1–KLH or with N-Pr MenB–TT conju-
gates in Freund’s adjuvant, as previously described (13).
Bactericidal assay. The bactericidal assay was performed as previously de-
scribed (13) with minor modifi  cations. In brief, bacteria were grown to the 
early stationary phase and mixed in equal volumes with serially diluted (rang-
ing from 1:3 to 1:768) heat-inactivated serum and undiluted baby rabbit 
complement (Cederlane). The reciprocal of the highest fi  nal serum dilution 
causing >50% killing of the inoculum was recorded as the bactericidal titer. 
Because the lowest fi  nal serum dilution tested was 1:9, the lower limit of de-
tection of the assay was a titer of 9. To assess inhibition of bactericidal activ-
ity, mixtures of twofold serial dilutions of inhibitor and diluted serum were 
incubated for 20 min at 37°C. After adding complement and bacteria, the 
test was completed as described above.
ELISA tests. To determine the isotype distribution of anti–MenB antibod-
ies, we used a whole bacteria ELISA (13). Anti–human PSA antibodies were 
detected by ELISA, using untreated or neuroaminidase-treated neuroblas-
toma CHP 212 cells, which express high levels of PSA. Both of these assays 
were performed exactly as previously described (13). Binding of serum anti-
bodies to the scFv G1 was measured by an identical ELISA test, with the ex-
ception that plates were sensitized with 2 μg/ml of purifi  ed scFv.
Infant rat model of passive protection. To study the protective eff  ects of 
sera obtained from immunized animals, we used an infant rat model, exactly 
as described previously (34). In brief, 5-d-old Wistar rats (Charles River 
Laboratories) were inoculated i.p. with serially diluted mouse sera and, 2 h 
later, challenged i.p. with 8 × 103 CFU MenB (strain 2996). Blood samples 
were obtained at 18 h after challenge, serially diluted, and plated onto choc-
olate agar (100 μl/plate). Because the lowest plated dilution was 1:10, the 
lower detection limit of the assay was 100 CFU/ml of blood. Pups were 
considered protected from bacteremia in the presence of sterile blood cul-
tures. All animal experiments reported in this paper were approved by the 
Department of Pathology and Experimental Microbiology Committee for 
Animal Studies and Istituto Superiore di Sanità .
Data expression and statistical analysis. Bactericidal titers were con-
verted to log2 titer values to calculate means and SDs and to assess statistical 
signifi  cance using one-way analysis of variance (ANOVA) and Student-
Keuls-Newman test. For the purpose of calculating means and SDs, sera with 
bactericidal activities below the detection threshold (i.e., with a titer <9) 
were given an arbitrary titer of 4.5 (i.e., half the lower detection limit). Dif-
ferences in the frequency of protected animals were analyzed using Fisher’s 
exact test.
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